![\"Robitussin](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/02\/shutterstock_1572556579-1024x683.jpg\")
<\/p>\n<\/p>\n
(Photo Credit: Jeffrey Budde\/Shutterstock)<\/p>\n
Robitussin class action settlement overview:\u00a0<\/p>\n
UPDATE: The Robitussin settlement<\/a> website is live. You have until May 12, 2025, to file a claim. A new proposed settlement to a series of class action lawsuits means that Robitussin cough medicine will no longer be advertised as \u201cnon-drowsy.\u201d.<\/p>\n On July 22, cough medicine consumers filed a motion in a New York federal court stating that GlaxoSmithKline has agreed to pay $4.5 million to settle claims it mislabeled Robitussin, plus remove the \u201cnon-drowsy\u201d marketing on packaging.<\/p>\n The settlement, if given final approval, would benefit anyone who bought the \u201cnon-drowsy\u201d Robitussin medicines nationwide from Feb. 16, 2016.<\/p>\n The covered products include \u201cany flavor Robitussin product containing [dextromethorphan hydrobromide] and marketed as non-drowsy,\u201d according to the motion.<\/p>\n DXM causes drowsiness, plaintiffs alleged<\/p>\n On Feb 16, 2022, Nancy Calchi filed a class action complaint<\/a> against GlaxoSmithKline, alleging that at least 16 Robitussin products containing dextromethorphan DXM prominently state on the front of their label that they are \u201cNon-Drowsy.\u201d\u00a0<\/p>\n She said that products containing DXM do cause drowsiness, and that drowsiness is a known side effect of DXM, but not known by the average consumer.<\/p>\n \u201cDefendants\u2019 misrepresentations allowed them to overcharge Plaintiff and other consumers for the Non-Drowsy Robitussin Products,\u201d she claimed.<\/p>\n Months later, on April 5, 2022, plaintiff Stacey Papalia filed another class action lawsuit<\/a> against Glaxosmithkline alleging it falsely advertises that its Robitussin brand cough medicines are non-drowsy.\u00a0<\/p>\n Papalia sought to represent a New York class of consumers who purchased Robitussin cough suppressants manufactured by Glaxosmithkline that contain DXM and that were represented as being \u201cnon-drowsy.\u201d\u00a0<\/p>\n Papalia claimed that Glaxosmithkline marketed its Robitussin cough medicines containing DXM as \u201cnon-drowsy\u201d so that it can sell more and \u201cboost its revenues.\u201d<\/p>\n Complaints consolidated<\/p>\n In their consolidated complaint, the plaintiffs alleged violations of various state consumer laws as well as breach of warranty claims.<\/p>\n Thanks to the settlement, class members can expect to come away with anywhere from $1.50 to $4.75 per claim, depending on how many claims are submitted, according to the motion.\u00a0<\/p>\n Attorneys will seek up to one-third of the settlement fund, the motion said.\u00a0<\/p>\n The class actions came as another class action lawsuit<\/a> was filed against Tylenol, with similar claims. Previously, a class action was filed against Procter & Gamble<\/a>, claiming its popular cough medicine DayQuil is falsely marketed as being non-drowsy.<\/p>\n What do you think of this Robitussin class action settlement? Let us know in the comments.<\/p>\n The consumers are represented by Jonas B. Jacobson and Simon Franzini of Dovel & Luner LLP.<\/p>\n The Robitussin class action settlements are Nancy Calchi v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al., Case No. 7:22-cv-01341, and Stacey Papalia v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, Case No. 7:22-cv-02630, both in the U.S. District Court for the Southern District of New York.<\/p>\n Read About More Class Action Lawsuits & Class Action Settlements:<\/p>\n \t\t\t\tWe tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.<\/p>\n “*” indicates required fields<\/p>\n","protected":false},"excerpt":{"rendered":"(Photo Credit: Jeffrey Budde\/Shutterstock) Robitussin class action settlement overview:\u00a0 UPDATE: The Robitussin settlement website is live. You have…\n","protected":false},"author":2,"featured_media":431231,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[103456,18996,102,6591,56,54,55],"class_list":{"0":"post-431230","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-a-new","9":"tag-featured-news","10":"tag-health","11":"tag-medication","12":"tag-uk","13":"tag-united-kingdom","14":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/431230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=431230"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/431230\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/431231"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=431230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=431230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=431230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nWho: GlaxoSmithKline has agreed to pay $4.5 million to end claims that it falsely advertised Robitussin cough medicine.\u00a0
\nWhy: The plaintiffs alleged the product was marketed as \u201cnon-drowsy\u201d when it can cause drowsiness.
\nWhere: The Robitussin settlement was filed in a New York federal court.<\/p>\n